ATE216239T1 - Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden - Google Patents

Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden

Info

Publication number
ATE216239T1
ATE216239T1 AT97301172T AT97301172T ATE216239T1 AT E216239 T1 ATE216239 T1 AT E216239T1 AT 97301172 T AT97301172 T AT 97301172T AT 97301172 T AT97301172 T AT 97301172T AT E216239 T1 ATE216239 T1 AT E216239T1
Authority
AT
Austria
Prior art keywords
tissue damage
reductase inhibitor
cardiological
aldose reductase
reduce non
Prior art date
Application number
AT97301172T
Other languages
English (en)
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE216239T1 publication Critical patent/ATE216239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97301172T 1996-02-29 1997-02-21 Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden ATE216239T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
ATE216239T1 true ATE216239T1 (de) 2002-05-15

Family

ID=21756300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97301172T ATE216239T1 (de) 1996-02-29 1997-02-21 Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden

Country Status (14)

Country Link
US (1) US6127367A (de)
EP (1) EP0792643B1 (de)
JP (1) JPH09316003A (de)
KR (1) KR970061252A (de)
CN (1) CN1081460C (de)
AT (1) ATE216239T1 (de)
AU (1) AU724327B2 (de)
CA (1) CA2198564C (de)
DE (1) DE69711972T2 (de)
DK (1) DK0792643T3 (de)
ES (1) ES2172748T3 (de)
IL (1) IL120264A0 (de)
PT (1) PT792643E (de)
ZA (1) ZA971717B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982306A3 (de) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph von Zopolrestat Monohydrat
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002098421A1 (en) * 2001-06-05 2002-12-12 University Of Maryland, Baltimore Novel treatment for neurological and psychiatric disorders
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
AU2006325947B2 (en) * 2005-12-16 2011-09-01 Hirosaki University Agent for prevention and treatment of acute renal failure
AU2007218709A1 (en) * 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8536212B2 (en) * 2007-01-31 2013-09-17 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
EP2848252A3 (de) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose-Reduktase-Inhibitoren zur Behandlung von Uveitis
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
EP2220216A4 (de) * 2007-11-15 2013-03-20 Univ Laval Verfahren zur regulation der prostaglandin f-synthase- (pgfs-)aktivität von akr1b1 und verwendungen davon
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
US10443185B2 (en) 2016-10-19 2019-10-15 Spectrum Brands, Inc. Portable steam generator base for iron
US20240033263A1 (en) 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492706A (en) * 1983-08-01 1985-01-08 American Home Products Corporation Method of lowering lipid levels
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (de) * 1987-10-08 1990-10-03 Ethyl Corporation Hühnerfutter
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
JP3049284B2 (ja) * 1990-11-07 2000-06-05 株式会社三和化学研究所 ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
CA2208485A1 (en) * 1994-12-22 1996-06-27 Ravichandran Ramasamy Method for protecting the heart from ischemia
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
ES2172748T3 (es) 2002-10-01
CN1081460C (zh) 2002-03-27
US6127367A (en) 2000-10-03
CA2198564A1 (en) 1997-08-29
IL120264A0 (en) 1997-06-10
EP0792643B1 (de) 2002-04-17
JPH09316003A (ja) 1997-12-09
DK0792643T3 (da) 2002-07-22
CN1168794A (zh) 1997-12-31
ZA971717B (en) 1998-08-27
DE69711972T2 (de) 2002-08-29
AU724327B2 (en) 2000-09-14
KR970061252A (ko) 1997-09-12
EP0792643A1 (de) 1997-09-03
MX9701533A (es) 1998-06-30
CA2198564C (en) 2000-06-27
AU1501097A (en) 1997-09-04
PT792643E (pt) 2002-08-30
DE69711972D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
ATE216239T1 (de) Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden
SE0004112D0 (sv) Stötfångarskena
DE59812714D1 (de) Optische anordnung zur symmetrierung der strahlung eines oder mehrerer übereinander angeordneter hochleistungsdiodenlaser
ES2122283T3 (es) Inhibicion del crecimiento capilar.
FI954270L (fi) Lisävoimanlähde merialuksia varten
ATE161536T1 (de) Neue mercaptoacetylamid-derivate zur verwendung als enkephalinase- und ace-hemmer
AR015379A1 (es) Ascorbil-fosforil-colesterol
NO952977D0 (no) Aminoduhydro-kosopurinyl-metoksypropandiolderivater
FI961797L (fi) Stabiloitu prostaglandiini E1
DE69020394D1 (de) Aldose-Reductase-Inhibitor.
HK168195A (en) Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AR029984A1 (es) Metodo para reducir las exacerbaciones asociadas copd ambito
DK0791355T3 (da) Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi
AU7358691A (en) Tenidap as an inhibitor of the release of elastage by neutrophils
WO2001079915A3 (en) Diffraction grating in the whispering gallery mount
FI924440A7 (fi) Heterosykliset yhdisteet aldoosireduktaasi-inhibiitteinä
DE60026272D1 (de) Verwendung eines Papillarfibroblast-spezifischen Antikörpers als Marker der Hautqualität
WO2001087848A3 (en) Synthesis procedure for biphenylimidazolyl-(1)-phenylmethane and related compounds
DK0721781T3 (da) Reduktion af fedtvæv under anvendelse af kollagenase
FI960371L (fi) Tiatsolijohdannaisia lipoksigenaasi-inhibiittoreina
RU96108459A (ru) Антифриз
CA2109516A1 (en) Inhibitors of cathepsin g and elastase for preventing connective tissue degradation
ATE166586T1 (de) Ganzkörper-bräunungsgerät
UA49438A (uk) Спосіб відтинання надлишку низведеної кишки
KR970052165U (ko) 압축기의 방진메스

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee